CFM
KNSA icon

Catalyst Funds Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Catalyst Funds Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$857K Hold
13,400
– – 0.05% 312
2026
Q1 		$645K Hold
13,400
– – 0.11% 210
2025
Q4 		$553K Hold
13,400
– – 0.13% 164
2025
Q3 		$520K Sell
13,400
-4,400
-25% -$143K 0.08% 229
2025
Q2 		$493K Buy
+17,800
New +$453K 0.14% 199
2024
Q4 		– Sell
-4,600
Closed -$115K – 818
2024
Q3 		$115K Buy
+4,600
New +$112K 0.03% 459

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Catalyst Funds Management's KNSA Position: Q2 2026 in Review

Catalyst Funds Management held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 13,400 shares worth $857K. The position accounts for 0.05% of the portfolio, ranked #312.

Catalyst Funds Management first reported a position in KNSA in Q3 2024 and has held it in 6 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Catalyst Funds Management held 13,400 shares of Kiniksa Pharmaceuticals worth $857K as of Q2 2026.
  • Catalyst Funds Management left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up 0.05% of Catalyst Funds Management's portfolio in Q2 2026, its #312 holding.
  • Catalyst Funds Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.